Limits...
Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer.

Kim ST, Jang HL, Lee J, Park SH, Park YS, Lim HY, Choi MG, Bae JM, Sohn TS, Noh JH, Kim S, Kim KM, Kang WK, Park JO - Transl Oncol (2015)

Bottom Line: Clinicopathological factors such as age, Lauren classification, sex, tumor infiltration, lymph node metastasis, and histologic grade did not show a statistically significant association with the methylation status of the IGFBP-3 promoter.Patients with a hypermethylated IGFBP-3 promoter had similar 8-year disease-free survival compared with those without a hypermethylated IGFBP-3 promoter (73% vs 75%, P = .78).In subgroup analyses, females, but not males, seemed to have poorer prognosis for DFS and OS in the subset of patients with IGFBP-3 methylation as compared with those without IGFBP-3 methylation (8-year DFS: 55.6% vs 71.6%, P = .3694 and 8-year overall survival: 55.6% vs 68.4%, P = .491, respectively) even with no statistical significance.

View Article: PubMed Central - PubMed

Affiliation: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

No MeSH data available.


Related in: MedlinePlus

Survival analysis: Disease-free (A) and overall (B) survival curves according to the status of IGFBP-3 methylation.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4562974&req=5

f0010: Survival analysis: Disease-free (A) and overall (B) survival curves according to the status of IGFBP-3 methylation.

Mentions: We performed survival analyses according to the methylation status of the IGFBP-3 promoter (Figure 2). Disease recurrence was observed in 34 (24.6%) of 138 patients during the median follow-up period of 110.7 months. Stage IB/II gastric cancer patients with a hypermethylated IGFBP-3 promoter had a similar DFS following curative surgery as compared with those without IGFBP-3 methylation (5-year DFS: 73.1% vs 79.5%; IGFBP-3 methylation (+) vs IGFBP-3 methylation (−); P = .7840). Moreover, gastric cancer patients with IGFBP-3 methylation also demonstrated similar OS following curative surgery as compared with those without IGFBP-3 methylation (5-year OS: 80.7% vs 80.3%; IGFBP-3 methylation (+) vs IGFBP-3 methylation (−); P = .7848). The following variables were tested using backward stepwise Cox proportional hazards regression modeling: age (≤ 60 vs > 60), Lauren classification, sex (male vs female), tumor infiltration (T1/T2 vs T3/T4), lymph node (N0/N1 vs N2/N3), histologic grade, and the methylation status of the IGFBP-3 promoter. For DFS and OS in all patients, none of the factors tested had a predictive role with statistical significance at the univariate and multivariate level.


Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer.

Kim ST, Jang HL, Lee J, Park SH, Park YS, Lim HY, Choi MG, Bae JM, Sohn TS, Noh JH, Kim S, Kim KM, Kang WK, Park JO - Transl Oncol (2015)

Survival analysis: Disease-free (A) and overall (B) survival curves according to the status of IGFBP-3 methylation.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4562974&req=5

f0010: Survival analysis: Disease-free (A) and overall (B) survival curves according to the status of IGFBP-3 methylation.
Mentions: We performed survival analyses according to the methylation status of the IGFBP-3 promoter (Figure 2). Disease recurrence was observed in 34 (24.6%) of 138 patients during the median follow-up period of 110.7 months. Stage IB/II gastric cancer patients with a hypermethylated IGFBP-3 promoter had a similar DFS following curative surgery as compared with those without IGFBP-3 methylation (5-year DFS: 73.1% vs 79.5%; IGFBP-3 methylation (+) vs IGFBP-3 methylation (−); P = .7840). Moreover, gastric cancer patients with IGFBP-3 methylation also demonstrated similar OS following curative surgery as compared with those without IGFBP-3 methylation (5-year OS: 80.7% vs 80.3%; IGFBP-3 methylation (+) vs IGFBP-3 methylation (−); P = .7848). The following variables were tested using backward stepwise Cox proportional hazards regression modeling: age (≤ 60 vs > 60), Lauren classification, sex (male vs female), tumor infiltration (T1/T2 vs T3/T4), lymph node (N0/N1 vs N2/N3), histologic grade, and the methylation status of the IGFBP-3 promoter. For DFS and OS in all patients, none of the factors tested had a predictive role with statistical significance at the univariate and multivariate level.

Bottom Line: Clinicopathological factors such as age, Lauren classification, sex, tumor infiltration, lymph node metastasis, and histologic grade did not show a statistically significant association with the methylation status of the IGFBP-3 promoter.Patients with a hypermethylated IGFBP-3 promoter had similar 8-year disease-free survival compared with those without a hypermethylated IGFBP-3 promoter (73% vs 75%, P = .78).In subgroup analyses, females, but not males, seemed to have poorer prognosis for DFS and OS in the subset of patients with IGFBP-3 methylation as compared with those without IGFBP-3 methylation (8-year DFS: 55.6% vs 71.6%, P = .3694 and 8-year overall survival: 55.6% vs 68.4%, P = .491, respectively) even with no statistical significance.

View Article: PubMed Central - PubMed

Affiliation: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

No MeSH data available.


Related in: MedlinePlus